Receptor-specific positron emission tomography radiopharmaceuticals: /sup 75/Br-labeled butyrophenone neuroleptics

Conference · Fri Nov 01 00:00:00 EST 1985 · Trans. Am. Nucl. Soc.; (United States)

OSTI ID:5072710

Moerlein, S M; Stoecklin, G; Weinhard, K; Pawlik, G; Heiss, W D

Cerebral dopaminergic D/sub 2/ receptors are involved in several common disease states, such as schizophrenia, Parkinson's disease, and Huntington's chorea. The use of radiolabeled D/sub 2/ receptor-binding ligands with positron emission tomography (PET) to noninvasively quantitate D/sub 2/ receptor densities thus has potential application in medicine. Butyrophenone neuroleptics have a high in vitro and in vivo binding affinity for cerebral D/sub 2/ receptors, and due to the useful chemical and nuclear decay properties of /sup 74/Br (76% ..beta../sup +/, half-life = 1.6 h), the authors have evaluated radiobrominated bromospiperone (BSP), brombenperidol (BBP), and bromperidol (BP) as radiopharmaceuticals for use with PET.

• Research Organization: Kernforschungsanlage Juelich GmbH, West Germany
• OSTI ID: 5072710
• Report Number(s): CONF-851115-; TRN: 86-036997
• Journal Information: Trans. Am. Nucl. Soc.; (United States), Vol. 50; Conference: American Nuclear Society winter meeting, San Francisco, CA, USA, 10 Nov 1985
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
POSITRON COMPUTED TOMOGRAPHY
RADIOPHARMACEUTICALS
BROMINE 75
LABELLED COMPOUNDS
NEUROLOGY
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BROMINE ISOTOPES
COMPUTERIZED TOMOGRAPHY
DIAGNOSTIC TECHNIQUES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
EMISSION COMPUTED TOMOGRAPHY
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
ISOTOPES
MEDICINE
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
TOMOGRAPHY
550602* - Medicine- External Radiation in Diagnostics- (1980-)